Successful integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon.
Avelin F
AF
Aghokeng
Charles
C
Kouanfack
Martine
M
Peeters
Eitel
E
Mpoudi-Ngole
Eric
E
Delaporte
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D002163:Cameroon; D024921:Drug Resistance, Multiple, Viral; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D011760:Pyrrolidinones / Q000008:administration & dosage / Q000627:therapeutic use*; D000068898:Raltegravir Potassium
D019380:Anti-HIV Agents; D019428:HIV Integrase Inhibitors; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium